If there is a company that boasts of its market value and fast development is the Seattle Genetics. The company’s value is currently attributed at $10 billion and with more than 900 enrolled employees. The company is also top ranking as the largest biotech in Washington.
Among the key factors to their success have been their heavy investment in research and marketing. It is one of the companies that has been undergoing vast developments and expansions that ensures an employment of more than 50 employees every year.
From the latest news from the directors of the company, they are currently in research to coming up with a drug to treat Hodgkin lymphoma. This is a cancer of the lymph systems that spread too fast to other body organs. They were captured claiming that if the ongoing expansive tests prove positive, its sales are expected to take off.
According to Clay Siegall, the co-founder and the current CEO of the company, Seattle Genetics is emerging to be a global, oncology and a multiproduct company. In line with this statement, he introduces a long list of the drugs that the company is dire to sell. He also points out on his plans to build the company not only to a great company but also to a larger company as so many biotech firms do.
It is true Siegalls ambitions are realistic more so when he talks of handling the complexities of the company to international marketing of its newer drugs. Under his leadership at Seattle, the company has made remarkable achievements and developments.
Back to his history, Dr. Clay Siegall is a man who has always led a successful life in all his previous engagements. Before he founded the Seattle Genetics, he was working with the Bristol Myers Squibb Pharmaceutical Research Institute from 1991 to 1997. Before this, he had also worked with the National Institute of Health between 1988 and 1991.
His career was all shaped by his commitment to his education. He is a degree holder in zoology from the University of Maryland. After his degree course, he also proceeded to George Washington University where he received a PhD in Genetics.
In the current position, Clay Siegel serves as a Board of Directors at the Alder BioPharmaceuticals which is a private biotechnology company. More to this, he is also an author with more than 70 publications and 15 patents. Through the companies that he has made worked with, he has come to be recognized as a man who has always demonstrated his ability to dedicate his time and focus on his duties.